Literature DB >> 17259978

Activating gene expression in mammalian cells with promoter-targeted duplex RNAs.

Bethany A Janowski1, Scott T Younger, Daniel B Hardy, Rosalyn Ram, Kenneth E Huffman, David R Corey.   

Abstract

The ability to selectively activate or inhibit gene expression is fundamental to understanding complex cellular systems and developing therapeutics. Recent studies have demonstrated that duplex RNAs complementary to promoters within chromosomal DNA are potent gene silencing agents in mammalian cells. Here we report that chromosome-targeted RNAs also activate gene expression. We have identified multiple duplex RNAs complementary to the progesterone receptor (PR) promoter that increase expression of PR protein and RNA after transfection into cultured T47D or MCF7 human breast cancer cells. Upregulation of PR protein reduced expression of the downstream gene encoding cyclooygenase 2 but did not change concentrations of estrogen receptor, which demonstrates that activating RNAs can predictably manipulate physiologically relevant cellular pathways. Activation decreased over time and was sequence specific. Chromatin immunoprecipitation assays indicated that activation is accompanied by reduced acetylation at histones H3K9 and H3K14 and by increased di- and trimethylation at histone H3K4. These data show that, like proteins, hormones and small molecules, small duplex RNAs interact at promoters and can activate or repress gene expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259978     DOI: 10.1038/nchembio860

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  219 in total

1.  SaRNA-mediated activation of TRPV5 reduces renal calcium oxalate deposition in rat via decreasing urinary calcium excretion.

Authors:  Tao Zeng; Xiaolu Duan; Wei Zhu; Yang Liu; Wenqi Wu; Guohua Zeng
Journal:  Urolithiasis       Date:  2017-08-03       Impact factor: 3.436

Review 2.  Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression.

Authors:  Keith T Gagnon; David R Corey
Journal:  Nucleic Acid Ther       Date:  2012-01-27       Impact factor: 5.486

Review 3.  Promoter-associated RNAs and promoter-targeted RNAs.

Authors:  Bing-Xue Yan; Jin-Xia Ma
Journal:  Cell Mol Life Sci       Date:  2012-03-14       Impact factor: 9.261

Review 4.  Minireview: Switching on progesterone receptor expression with duplex RNA.

Authors:  Bethany A Janowski; David R Corey
Journal:  Mol Endocrinol       Date:  2010-06-30

Review 5.  Molecular Regulation of Parturition: A Myometrial Perspective.

Authors:  Nora E Renthal; Koriand'r C Williams; Alina P Montalbano; Chien-Cheng Chen; Lu Gao; Carole R Mendelson
Journal:  Cold Spring Harb Perspect Med       Date:  2015-09-03       Impact factor: 6.915

6.  Upregulation of RECK gene expression by small double-stranded RNA targeting the promoter region.

Authors:  F Sakurai; Y Nanjo; S Okamoto; M Tachibana; H Mizuguchi
Journal:  Cancer Gene Ther       Date:  2014-03-21       Impact factor: 5.987

7.  Inducing gene expression by targeting promoter sequences using small activating RNAs.

Authors:  Ji Wang; Robert F Place; Victoria Portnoy; Vera Huang; Moo Rim Kang; Mika Kosaka; Maurice Kwok Chung Ho; Long-Cheng Li
Journal:  J Biol Methods       Date:  2015-03-11

Review 8.  RNA activation technique and its applications in cancer research.

Authors:  Xiao-Yu Wang; Long Yuan; Yan-Ling Li; Si-Jie Gan; Lin Ren; Fan Zhang; Jun Jiang; Xiao-Wei Qi
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

9.  Profiling RE1/REST-mediated histone modifications in the human genome.

Authors:  Deyou Zheng; Keji Zhao; Mark F Mehler
Journal:  Genome Biol       Date:  2009-01-27       Impact factor: 13.583

10.  ROS3 is an RNA-binding protein required for DNA demethylation in Arabidopsis.

Authors:  Xianwu Zheng; Olga Pontes; Jianhua Zhu; Daisuke Miki; Fei Zhang; Wen-Xue Li; Kei Iida; Avnish Kapoor; Craig S Pikaard; Jian-Kang Zhu
Journal:  Nature       Date:  2008-09-24       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.